Online inquiry

IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ9595MR)

This product GTTS-WQ9595MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets VSIR gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_022153.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 64115
UniProt ID Q9H7M9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-VSIR, JNJ-61610588(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ9595MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6814MR IVTScrip™ mRNA-Anti-STEAP1, DSTP-3086S(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA DSTP-3086S
GTTS-WQ11923MR IVTScrip™ mRNA-Anti-GUCY2C, MLN2045(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN2045
GTTS-WQ4587MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-986004
GTTS-WQ13727MR IVTScrip™ mRNA-Anti-ERBB2, RC48-0(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA RC48-0
GTTS-WQ6422MR IVTScrip™ mRNA-Anti-HA, CT-P22(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CT-P22
GTTS-WQ2682MR IVTScrip™ mRNA-Anti-SOST, AMG 785 (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 785
GTTS-WQ8376MR IVTScrip™ mRNA-Anti-TACSTD2, aTROP2S7(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA aTROP2S7
GTTS-WQ12870MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPN-305
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW